DERMADIS SAS

Dermadis is a Biotech company developing breakthrough drugs to treat inflammatory skin disorders by controlling specific biological pathways. Dermadis’ lead  compound is currently in final preclinical development for the severe orphan disease Netherton Syndrome. For this indication Dermadis has received  Orphan Drug Designation status by the EMEA and FDA.

Additionally, Dermadis' compound family based on engineered forms of human proteins (biomimetics) has also confirmed potential in related large market dermatology indications (e.g. atopic dermatitis or rosacea) and various skin conditions (e.g. reactive skin, sensitive skin, itchy skin). Therefore, Dermadis has set up collaborations with companies active in dermo-cosmetics and veterinary medicine in order to supply them with such active ingredients.